Show simple item record

dc.contributor.authorRack, Samuel
dc.contributor.authorFeeney, L.
dc.contributor.authorMistry, H.
dc.contributor.authorBetts, G.
dc.contributor.authorHarrington, K. J.
dc.contributor.authorMetcalf, Robert
dc.date.accessioned2022-11-30T10:21:27Z
dc.date.available2022-11-30T10:21:27Z
dc.date.issued2022en
dc.identifier.citationRack S, Feeney L, Mistry H, Betts G, Harrington KJ, Metcalf R. The prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301789.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.6087en
dc.identifier.urihttp://hdl.handle.net/10541/625812
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.6087en
dc.titleThe prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentChristie Hospital NHS Foundation Trust, Manchester,en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record